Latest news with #IndiaMart
India Gazette
15-07-2025
- Business
- India Gazette
"UAE enjoys productive investment ties with every Indian state": UAE Minister of State for Foreign Trade after meeting MP CM
Dubai [UAE], July 15 (ANI): UAE Minister of State for Foreign Trade, Thani bin Ahmed Al Zeyoudi, emphasised the robust trade and investment relationships between the UAE and all Indian states following a meeting with Madhya Pradesh Chief Minister Mohan Yadav, who was on an official visit to the country. In a post on X, the UAE Minister of State for Foreign Trade, Al Zeyoudi, highlighted the potential for enhanced cooperation in high-value sectors during his meeting with the MP CM on Monday. 'The UAE enjoys productive trade and investment ties with every state in India. Today, I met Dr Mohan Yadav, CM Madhya Pradesh, to explore how we can strengthen cooperation in high-value sectors such as agriculture, manufacturing and logistics,' he stated in a post on X. The Madhya Pradesh CM following his meeting with Al Zeyoudi, stated that both of them discussed the investment opportunities in the state under the India-UAE Comprehensive Economic Partnership Agreement (CEPA) and I2U2 collaboration and stated that MP offers a suitable industrial base, policy support and necessary infrastructure for the UAE's investment in various sectors like textiles, pharma, smart manufacturing, renewable energy, and food processing. 'Today, on the second day of the Dubai visit, I met with the UAE Minister of State for Foreign Trade, H.E. Dr. Thani Bin Ahmed Al Zeyoudi, and held extensive discussions on the immense investment opportunities in Madhya Pradesh under the India-UAE Comprehensive Economic Partnership Agreement (CEPA) and I2U2 collaboration,' he stated in a post on X. 'Madhya Pradesh offers a suitable industrial base, policy support, and necessary infrastructure for UAE investments in sectors such as EV, textiles, pharma, smart manufacturing, renewable energy, and food processing. Additionally, there are vast opportunities for partnership in areas like mineral resources, tourism, healthcare, 'plug and play' industrial parks, and air cargo. This multidimensional collaboration based on CEPA and I2U2 will elevate India-UAE relations to new heights and prove significant in realising the vision of a 'Developed Madhya Pradesh',' he added. Notably, CM Yadav is scheduled to travel to Spain after concluding his visit to the UAE on Tuesday. Prior to his departure to Spain, Yadav will be visiting India Mart and meeting with DP World representatives. 'Madhya Pradesh Becomes the Preferred Choice for Investors in Dubai The second day of Chief Minister Dr. Mohan Yadav's Dubai visit was dedicated to one-on-one meetings with prominent industrialists. Today, on the third day of the foreign visit, the Chief Minister will meet with representatives of DP World and visit India Mart,' The MP Chief Minister's Office stated in a post on X. The visit, from July 13 to 19, aims to bring global investment to Madhya Pradesh, encourage technology sharing, and create new job opportunities under the umbrella of 'Global Dialogue 2025.' (ANI)
The Print
29-06-2025
- Health
- The Print
Shefali Jariwala death: What it reveals about fake cosmetologists
While the Indian Association of Dermatologists, Venereologists, and Leprologists (IADVL) is raising the issue and writing to health officials, we need the public to stop enabling this madness. There is absolutely no degree called 'cosmetology'. Yet, the business continues to flourish in India, the only country where people die from hair transplants. In May, Anushka Tiwari, a Kanpur-based dentist, was arrested after two men died following hair transplant procedures performed by her. It's a crisis. What happened to actor-model Shefali Jariwala should never have happened. As a dermatologist with over 14 years of experience, I've watched in horror as unqualified practitioners turn anti-ageing treatments into a deadly gamble. This isn't just tragic—it's criminal. How to spot a fake doctor before it's too late It doesn't matter how convincing an Instagram ad looks—always verify your doctor's credentials. Here's how: Go to your state medical council's website. Search the doctor's name. Check their MBBS degree and specialisation. If they're not listed, run. If someone calls themself a 'cosmetologist' without a medical degree to show for it, run faster. Also read: Is 30 a good age to start using anti-ageing products? Here are some dos and don'ts Glutathione scam: Online buying is Russian roulette Every week, young women walk into my clinic with glutathione vials bought from IndiaMart or some shady online sellers, expecting me to inject them. My answer? Absolutely not. You don't know if the cold chain was maintained. You don't know if it's counterfeit. You don't know if it's even safe for human use. Glutathione is a powerful antioxidant, but when misused—especially in unregulated doses for years—it can turn toxic. According to media reports, Shefali had been on these injections for five to six years. Was it under a dermatologist's supervision? Was it even real glutathione? We may never know. Golden rule you must remember It's not about avoiding treatments—it's about respecting them. Here's my professional mantra: A qualified dermatologist knows: Precise dosing – When glutathione is life-saving vs. when it's toxic Contraindications – Who should never receive certain treatments Emergency protocols – What to do when things go wrong (because sometimes they do) Also read: Debunking anti-ageing myths. Treatments, luxury creams can't rewind the biological clock Anti-ageing done right vs reckless experimentation Anti-ageing medicine isn't the villain—quacks are. When performed by licensed dermatologists, treatments like NAD drips, NMN, and even glutathione are safe. But here's what else you need: A balanced lifestyle – No injection replaces sleep, nutrition, and exercise. Realistic expectations – Aging is natural; our goal is healthy aging, not magic. Zero tolerance for non-doctors – Dentists doing Botox? A disaster waiting to happen. Plea to the public: Stop trusting social media over science Good dermatologists don't have flashy Instagram ads because we're too busy treating patients. Meanwhile, quacks spend fortunes on SEO, luring victims with cheap prices and empty promises. 'Anti-ageing means prolonging life—not losing it to negligence. If Shefali's death exposes unqualified practitioners, let it be a turning point,' said Dr Rajiv Sharma, president of IADVL. So TL;DR: Never let a non-dermatologist inject you. Ever. Never buy medications online from platforms like Amazon Never ever prioritise trends over safety. Shefali Jariwala's death should be a wake-up call. Demand accountability. Choose wisely. And please stop letting influencers play doctor. Dr Deepali Bhardwaj is a Consultant Dermatologist, Max Hospital, Saket. She is also an anti-allergy specialist, laser surgeon and internationally trained aesthetician. She tweets @dermatdoc. Views are personal. (Edited by Prashant)
Time of India
25-06-2025
- Business
- Time of India
Indiamart surges 6% as Nuvama turns bullish, lifts target to Rs 3,800, brokerage sees subscriber revival
Shares of IndiaMart Intermesh jumped over 6% to Rs 2,650 on Tuesday after Nuvama Institutional Equities upgraded the stock to 'Buy' from 'Reduce' and raised the target price to Rs 3,800, citing an impending demand upcycle. "We upgrade IndiaMart from 'REDUCE' to 'BUY' — following earlier downgrades in Oct-23 to 'HOLD' and Oct-24 to 'REDUCE' — as we believe the business is entering a new demand upcycle," the brokerage said in a note, according to an ET report. IndiaMart shares were trading at a one-year forward price-to-earnings multiple of 28x, compared to the historical average of 45x. Despite Tuesday's rally, the stock remains down nearly 3% over the past year. Nuvama said the new cycle is expected to begin with an improvement in traffic and unique business enquiries, followed by a rise in net subscriber additions and an eventual acceleration in collection growth. The brokerage has increased its earnings estimates by 9–10% for FY26 and FY27, driven by higher revenue projections, though it has trimmed profitability expectations. The target valuation multiple was revised upwards from 22x to 35x — the level prior to the October downgrade — citing improved growth prospects. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 75% off installation for LeafFilter LeafFilter Gutter Protection Learn More Undo The new price target is Rs 3,800, up from Rs 2,100 earlier. According to Nuvama, IndiaMart's management has undertaken structural reforms including platform improvements, partial insourcing of the sales force, and increased investment in branding and marketing. It also highlighted a shift in platform dynamics, noting that the company has reduced the number of supplier enquiries from seven to fewer than four, helping cut supplier competition. 'Moreover, investing in attracting buyers will ensure there is plenty of enquiry volume for everyone to flourish. We believe headwinds have bottomed out and these investments are ready to deliver results. We reckon an improvement in subscriber additions shall occur by Q2/Q3, which will lead to a revival in collection growth,' the report added, quoting Nuvama. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
25-06-2025
- Business
- Time of India
IndiaMart shares get Rs 3,800 target price, stock jumps 6%
Shares of IndiaMart Intermesh jumped around 6% to the day's high of Rs 2,650 on the BSE today after domestic brokerage firm Nuvama Institutional Equities upgraded the stock to Buy and raised the target price to Rs 3,800. 'We upgrade IndiaMart from 'REDUCE' to 'BUY'—following earlier downgrades in Oct-23 to 'HOLD' and Oct-24 to 'REDUCE'—as we believe the business is entering a new demand upcycle,' Nuvama said. IndiaMart shares were trading at a one-year forward P/E of 28x, compared to the historical average of 45x. The stock is still down around 3% over the past year. Arguing that a new demand cycle will begin—starting with improvement in traffic and unique business enquiries, followed by a rise in net subscriber additions and, ultimately, an acceleration in collection growth—the brokerage said valuation should rerate as the management focuses on enhancing customer engagement metrics. 'We are increasing earnings estimates by ~9–10% for FY26E/27E, driven by higher revenue growth, though we are lowering profitability expectations. Live Events We are raising the target valuation multiple from 22x to 35x—the same as the pre-downgrade level—due to improving growth prospects, thereby increasing the target price from Rs 2,100 to Rs 3,800,' Nuvama noted. Stating that the company's management has made several changes to address structural issues—such as improving the platform, insourcing part of the sales force, and now investing in branding and marketing—Nuvama said IndiaMart is on the right path. The company has reduced the number of supplier enquiries from ~7 to fewer than 4, thereby reducing competition among suppliers. 'Moreover, investing in attracting buyers will ensure there is plenty of enquiry volume for everyone to flourish. We believe headwinds have bottomed out and these investments are ready to deliver results. We reckon an improvement in subscriber additions shall occur by Q2/Q3, which will lead to a revival in collection growth,' it added.
Economic Times
25-06-2025
- Business
- Economic Times
IndiaMart shares get Rs 3,800 target price, stock jumps 6%
Shares of IndiaMart Intermesh jumped around 6% to the day's high of Rs 2,650 on the BSE today after domestic brokerage firm Nuvama Institutional Equities upgraded the stock to Buy and raised the target price to Rs 3,800. ADVERTISEMENT 'We upgrade IndiaMart from 'REDUCE' to 'BUY'—following earlier downgrades in Oct-23 to 'HOLD' and Oct-24 to 'REDUCE'—as we believe the business is entering a new demand upcycle,' Nuvama said. IndiaMart shares were trading at a one-year forward P/E of 28x, compared to the historical average of 45x. The stock is still down around 3% over the past year. Arguing that a new demand cycle will begin—starting with improvement in traffic and unique business enquiries, followed by a rise in net subscriber additions and, ultimately, an acceleration in collection growth—the brokerage said valuation should rerate as the management focuses on enhancing customer engagement metrics.'We are increasing earnings estimates by ~9–10% for FY26E/27E, driven by higher revenue growth, though we are lowering profitability are raising the target valuation multiple from 22x to 35x—the same as the pre-downgrade level—due to improving growth prospects, thereby increasing the target price from Rs 2,100 to Rs 3,800,' Nuvama noted. ADVERTISEMENT Stating that the company's management has made several changes to address structural issues—such as improving the platform, insourcing part of the sales force, and now investing in branding and marketing—Nuvama said IndiaMart is on the right path. The company has reduced the number of supplier enquiries from ~7 to fewer than 4, thereby reducing competition among suppliers.'Moreover, investing in attracting buyers will ensure there is plenty of enquiry volume for everyone to flourish. We believe headwinds have bottomed out and these investments are ready to deliver results. ADVERTISEMENT We reckon an improvement in subscriber additions shall occur by Q2/Q3, which will lead to a revival in collection growth,' it added. (You can now subscribe to our ETMarkets WhatsApp channel)
